SUPN — Supernus Pharmaceuticals, Inc.

Summary of Supernus Pharmaceuticals Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $211.6 million, up 21% year-over-year; excluding Trokendi XR and Oxtellar XR, revenue increased 34%.
• Net Product Sales: $158.1 million; collaboration revenues from ZURZUVAE at $32.8 million; royalty and licensing revenues at $20.7 million.
• Full Year 2025 Revenue: Record $719 million, a 27% increase excluding Trokendi XR and Oxtellar XR.
• Operating Loss: GAAP operating loss of $4 million in Q4 2025, compared to a profit of $21.4 million in Q4 2024; full year GAAP net loss of $38.6 million.
• Cash Position: Approximately $309 million in cash and equivalents, down from $454 million in 2024, primarily due to the Sage acquisition.
• Adjusted Operating Earnings: $48.5 million in Q4 2025, slightly up from $48.3 million in Q4 2024; full year adjusted operating earnings at $158.7 million, down from $183.7 million in 2024.

2. Strategic Updates and Business Highlights

• Growth Products: Strong performance from four key products: Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO, which together accounted for 76% of total revenues in Q4.
• ONAPGO Launch: Generated $8.9 million in Q4, with total sales of $17.3 million since launch; demand remains healthy despite supply constraints.
• ZURZUVAE Performance: Collaboration revenues of $32.8 million in Q4; U.S. sales increased 187% year-over-year.
• R&D Initiatives: Ongoing trials for SPN-820 and SPN-817, with expectations for data in 2027; plans to retain certain early-stage assets from the Sage acquisition for internal development.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected total revenues between $840 million and $870 million, including $45 million to $70 million from ONAPGO.
• Expense Projections: Combined R&D and SG&A expenses anticipated to be between $620 million and $650 million.
• Operating Income/Loss: Expected to range from breakeven to a loss of $30 million; non-GAAP operating earnings projected between $140 million and $170 million.

4. Bad News, Challenges, or Points of Concern

• Operating Losses: Significant GAAP operating losses reported for both Q4 and full year 2025, contrasting with profits in the previous year.
• Cash Decrease: Notable reduction in cash reserves due to acquisition costs, raising concerns about liquidity for future investments.
• Supply Constraints: Ongoing supply issues for ONAPGO, although management is working to resolve these with existing and new suppliers.
• Gross to Net Pressure: Potential temporary drag on ONAPGO's gross to net in early 2026 due to backlog processing and patient enrollment dynamics.

5. Notable Q&A Insights

• Supply Chain Management: Management confirmed that the current supplier can meet the 2026 revenue guidance for ONAPGO, with a second supplier expected to come online in 2027.
• Demand for ONAPGO: The demand remains strong, with 1,800 enrollment forms submitted, but the conversion to actual patients may be affected by processing delays.
• ZURZUVAE Strategy: The focus will be on both expanding the number of prescribers and increasing volume among existing prescribers, with ongoing educational efforts to raise awareness and confidence in treating postpartum depression.
• R&D Priorities: While early-stage assets from the Sage acquisition will be evaluated, the focus remains on late-stage products that can generate revenue in the near term.

This summary encapsulates the key points from Supernus Pharmaceuticals' Q4 2025 earnings call, highlighting both achievements and challenges as the company navigates its growth trajectory.